Company snapshot
- Ticker
- GERN
- Exchange
- NMS
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $693.87M
- Employees
- 258
- Currency
- USD
- Website
- https://www.geron.com
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase…
Latest coverage
- Geron: 3 Key Takeaways for Long-Term Investors
November 5, 2026